Phase II Trial of Vorinostat With Idarubicin and Cytarabine for Patients With Newly Diagnosed Acute Myelogenous Leukemia or Myelodysplastic Syndrome

PURPOSE: To evaluate the safety and efficacy of the combination of the histone deacetylase inhibitor vorinostat with idarubicin and ara-C (cytarabine) in patients with acute myelogenous leukemia (AML) or myelodysplastic syndrome (MDS). PATIENTS AND METHODS: Patients with previously untreated AML or...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:J Clin Oncol
Main Authors: Garcia-Manero, Guillermo, Tambaro, Francesco Paolo, Bekele, Nebiyou B., Yang, Hui, Ravandi, Farhad, Jabbour, Elias, Borthakur, Gautam, Kadia, Tapan M., Konopleva, Marina Y., Faderl, Stefan, Cortes, Jorge E., Brandt, Mark, Hu, Yumin, McCue, Deborah, Newsome, Willie Mae, Pierce, Sherry R., de Lima, Marcos, Kantarjian, Hagop M.
Formato: Artigo
Idioma:Inglês
Publicado em: American Society of Clinical Oncology 2012
Assuntos:
ORIGINAL REPORTS
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC4879705/
https://ncbi.nlm.nih.gov/pubmed/22585696
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.2011.38.3265
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados